<DOC>
	<DOCNO>NCT02747953</DOCNO>
	<brief_summary>The program provide early access investigational drug gilotrif patient advance non-small cell lung cancer fail least 6 month erlotinib gefitinib . The Compassionate Use Programme also provide additional safety information gilotrif use .</brief_summary>
	<brief_title>Gilotrif ( Afatinib ) Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib Gefitinib</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Patients pathologically confirm diagnosis adenocarcinoma lung Stage IV progressive disease follow least one line platinumbased cytotoxic chemotherapy 2 . Patients progress clinical benefit erlotinib gefitinib : clinical benefit define stable disease least 6 month , complete partial response , presence activate mutation epidermal growth factor ( EGF ) receptor family . 3 . No treatment option available . 4 . Male female patient age ≥18 year . 5 . Written inform consent consistent International Conference HarmonisationGood Clinical Practice ( ICHGCP ) guideline local law . 1 . Significant recent acute gastrointestinal disorder diarrhoea major symptom . 2 . Patients lifethreatening illness organ system dysfunction , opinion investigator , would compromise patient safety . 3 . History cardiac disease clinically significant , judged investigator uncontrolled cardiac disease ( include congestive heart failure , angina , myocardial infarction , arrhythmia , include New York Heart Association ( NYHA ) functional classification 3 ) . 4 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) ≥ three time upper limit normal ( related liver metastasis ≥ five time upper limit normal ) . 5 . Bilirubin ≥1.5 mg/dl 6 . Serum creatinine ≥ 1.5 time upper normal limit calculated/measured creatine clearance ≤ 45ml/min 7 . Women childbearing potential men able father child unwilling use medically acceptable method contraception treatment . 8 . Pregnancy breast feed . 9 . Preexisting Interstitial Lung Disease ( ILD ) . 10 . Patients suitable include afatinib clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>